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Abstract: Cardiovascular diseases are the
leading cause of death in the world. Coronary
artery diseases, atrial fibrillation or hypertensive
heart disease, are among the most important
cardiovascular disorders. Hypertension
represents a significant risk factor for
cardiovascular mortality; thus, control of high
blood pressure has become a priority to prevent
major complications. Although the choice of
drugs for treating hypertension remains
controversial, extensive clinical evidences point
to calcium channel blockers as first-line agents.
Diltiazem, a non-dihydropyridine calcium
channel blocker, is an effective and safe
antihypertensive drug, alone or in combination
with other agents. Diltiazem lowers myocardial
oxygen demand through a reduction in heart
rate, blood pressure, and cardiac contractility,
representing also a good alternative for the
treatment of stable chronic angina.
Furthermore, diltiazem reduces conduction in
atrioventricular node, which is also useful for
heart rate control in patients with atrial
fibrillation. In this review, clinical experts
highlight studies on diltiazem effectiveness and
safety for the treatment of several cardiovascularEnhanced content To view enhanced content for this
article go to www.medengine.com/Redeem/B884F0600
FC78158.
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INTRODUCTION
Calcium channel blockers (CCBs) or calcium
antagonists reduce the influx of calcium into the
cells. Inhibition of calcium channels in the
vessels results in vasodilation and,
consequently, a lowering of the blood pressure.
In the heart, this blockage reduces cardiac
contractility and slows atrioventricular
conduction velocities [1]. Thus, CCBs are used
to treat high blood pressure, alone or in
combination with other drugs. All guideline
committees consider CCBs an option for
first-line treatment of hypertension [2]. In
addition, some CCBs are also indicated for the
treatment of chronic stable angina or atrial
arrhythmias, such as diltiazem [3–5].
Extensive comparative trials have analyzed
diltiazem in patients with hypertension, chronic
angina, or atrial arrhythmias. The results
demonstrated that diltiazem is an effective and
safe antihypertensive agent [3]. Diltiazem also
reduces the frequency of angina episodes and
increases exercise tolerance [4, 5]. The
extended-release formulation of diltiazem allows
its administration once daily, optimizing
antihypertensive and antianginal therapies.
Diltiazem belongs to the non-dihydropyridine
CCBs. This subclass presents more negative
chronotropic and inotropic effects than the
dihydropyridine subclass and induces a significant
reduction of atrioventricular conduction rate; all of
these make non-dihydropyridines useful for acute
and chronic treatment as well as for prevention of
atrial arrhythmias [6].
The authors of this review, who are clinical
experts in cardiovascular diseases: (1) highlight
studies on the effectiveness and safety of
diltiazem for the treatment of hypertension,
stable chronic angina, and atrial arrhythmias;
and (2) make evidence-based recommendations
regarding the management of diltiazem in the
clinical practice, with specific description of the
dose most frequently used in each clinical
indication. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
DILTIAZEM IN THE TREATMENT
OF HYPERTENSION
Hypertension or high blood pressure is a
chronic condition in which the blood force
against the arteries walls is persistently elevated.
Untreated hypertension is a major risk factor for
a number of cardiovascular disorders. In this
regard, calcium antagonists are a first-line
treatment for hypertension [2]. Many studies
have demonstrated the effectiveness of
diltiazem for the treatment of high blood
pressure. Diltiazem can be used as
monotherapy or in association with other
antihypertensive drugs. The usual starting
doses are 120–240 mg/day, and it may be
increased up to 540 mg/day based on
individual patient needs. The dosage range
studied in clinical trials was 120–540 mg/day,
although current clinical experience with the
540 mg dose is limited [24].
Thus, two independent multicenter studies
assessed the safety and efficacy of various
once-daily doses of diltiazem in patients with
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mild-to-moderate hypertension [7]. In one
study, patients were randomly treated with
once-daily diltiazem (120, 240, 360, or
480 mg) or placebo for 4 weeks, and in the
second study, patients were assigned to
escalating dosages (180 mg/day for 2 weeks,
360 mg/day for 2 weeks, and then 540 mg/day
for 2 weeks). The data demonstrated that
once-daily doses higher than 120 mg
significantly lower systolic and diastolic blood
pressure compared to placebo. Additionally,
adverse events were mild and with an
incidence similar to placebo.
A later study analyzed the effects of
graded-release diltiazem versus ramipril on
early morning blood pressure and heart rate in
patients with hypertension [8]. The results
showed that evening administration of
diltiazem (240 mg titrated to 360 mg and to
540 mg) significantly reduced morning blood
pressure and heart rate compared to ramipril.
Diltiazem also led to a greater reduction in
diastolic blood pressure over the 24-h interval
after bedtime dosage. However, no difference
was found in 24-h systolic blood pressure
reduction among the two groups. Therefore,
the authors demonstrated diltiazem superiority
compared to ramipril and emphasized the
importance of managing high blood pressure
in the morning, when cardiovascular events
occur more frequently.
The NORDIL study [3], which enrolled 10,881
patients with diastolic blood pressure of
100 mmHg or more, analyzed the effectiveness
of diltiazem in reducing cardiovascular morbidity
and mortality. Patients were randomized to
receive diltiazem or diuretics, beta-blockers, or
both (diuretic/beta-blocker). The combined
primary endpoint was fatal and non-fatal stroke,
myocardial infarction, and other cardiovascular
death. Systolic and diastolic blood pressure was
effectively reduced in the diltiazem group and
diuretic/beta-blockergroups (reduction:20.3/18.7
vs. 23.3/18.7 mmHg, respectively; difference in
systolic reduction P\0.001). The incidence of the
primary endpoint was similar for the diltiazem
group and the diuretic and beta-blocker groups
(relative risk: 1.00; 95% confidence interval [CI]
0.87–1.15; P = 0.97). These results indicate that
180–360 mg of diltiazem reduced blood pressure
and prevented myocardial infarction to the same
extend than diuretics, beta-blockers or both.
However, fatal and non-fatal stroke was reduced
by 25% in the diltiazem group (relative risk: 0.80;
95% CI 0.65–0.99; P = 0.04). Although the
authors argue that this finding may be
attributable to chance, they also suggest that it
may indicate a novel role of diltiazem in
preventing cerebral stroke in hypertensive
patients. Similar results were found in the
diabetic subgroup.
A meta-analysis of 13 studies with 103,793
patients with hypertension found a decrease in
the risk of stroke among the CCB-treated group
compared to other antihypertensive drugs (odds
ratio 0.90; 95% CI 0.84–0.96; P = 0.002).
Whereas dihydropyridine CBBs presented a
lower risk of stroke, non-dihydropyridine
CCBs did not achieve significance. Thus, the
authors concluded that CBBs should be
considered in patients with hypertension with
increased risk of stroke [9].
DILTIAZEM IN THE TREATMENT
OF CHRONIC STABLE ANGINA
A number of studies have analyzed the effects of
diltiazem in stable and acute angina. It has been
shown that diltiazem increases tolerance to
exercise, likely due to its potent dilator effect
on coronary arteries, leading to reduction in
both heart rate and systemic blood pressure at
submaximal and maximal workloads [23].
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Although it is known that the risk of adverse
cardiovascular and cerebrovascular events is
higher during the morning hours, some
controversy exists in the literature regarding
the greater beneficial effect of diltiazem
administration in the evening. In this regard,
some authors have shown that once-daily
graded-release diltiazem dosed overnight
effectively increases exercise tolerance in
patients with angina pectoris. In a
multicenter, randomized, double blind,
placebo-controlled trial, the efficacy and safety
of once-daily diltiazem (180, 360 and 420 mg)
dosed at 10 pm was compared with placebo,
and with diltiazem 360 mg dosed once-daily at
8 am [10]. A total of 311 patients with
stable angina pectoris were subjected to a
treadmill stress test (standard Bruce protocol)
at baseline and at the end of the trial between
6 pm and 8 pm (for evening doses) and between
7 am and 11 am (for morning doses). The results
showed that all evening diltiazem doses
increased total duration of exercise compared
to placebo (P B 0.0201). Diltiazem 360 mg
dosed in the evening presented the greatest
increase in exercise tolerance, whereas the same
dose administered in the morning was not
different from placebo. The authors concluded
that bedtime diltiazem significantly increases
exercise tolerance in patients with angina
pectoris over the 24-h dosing interval. The
greatest improvement occurred in the morning
between 7 am and 11 am, which is the highest
cardiovascular risk period. Additionally,
diltiazem was safe and well tolerated.
However, other authors have found that
480 mg/day of diltiazem administered in the
AM or the PM to patients with stable angina was
equally effective in suppressing episodes of
ambulatory myocardial ischemia [11].
Several studies have evaluated the
antianginal effectiveness of diltiazem alone or
in combination with beta-blockers or other
CCBs. In a double-blind, randomized,
placebo-controlled study, patients were treated
four-times daily with 90 mg of diltiazem, 60 mg
of propranolol, or a combination of 90 mg of
diltiazem and 60 mg of propranolol [12]. The
results indicated that diltiazem was more
effective in improving exercise tolerance
(assessed by exercise-stress test and left
ventricular ejection fraction) than propranolol
or the combination of both [12]. Another study
compared the effects of propranolol,
propranolol-verapamil, propranolol-nifedipine,
and propranolol-diltiazem in patients with
chronic angina pectoris [13]. Although the
three combinations equally reduced the
incidence of angina attacks and decreased
ST-segment depression, propranolol-diltiazem
presented the lower incidence of adverse
clinical effects. Therefore, the authors reported
that propranolol-diltiazem should be
considered the first-choice combination when
beta- and CCB therapy is recommended [13].
Similarly, in a placebo, randomized,
double-blind protocol, patients with
stable angina pectoris received diltiazem
(180–360 mg/day) or nifedipine (30–120 mg/
day) for 2 weeks [14]. Patients who remained
symptomatic on both drugs during the
monotherapy were treated with a combination
of diltiazem and nifedipine. Although both
drugs alone reduced the frequency of angina
and amount of nitroglycerin treatment
compared to placebo, diltiazem was
significantly more effective in reducing the
episodes of ST-segment depression than
nifedipine. Additionally, diltiazem alone was
better tolerated than nifedipine alone at
maximal effective doses. The combination of
the two calcium blockers appeared to be
beneficial; however, an increase in side effects
was detected.
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DILTIAZEM AND ATRIAL
ARRHYTHMIAS
Calcium channel blockers are used to slow the
heart rate and reduce the strength of the cardiac
cell contraction in patients with atrial
fibrillation or supraventricular tachycardia
[15]. This statement is based on studies that
analyzed efficacy and safety of diltiazem for
heart rate control in patients with permanent
atrial fibrillation. One study compared the
effect of four daily single-drug regimens
(diltiazem 360 mg, verapamil 240 mg,
metoprolol 100 mg, and carvedilol 25 mg) on
reducing ventricular heart rate and
arrhythmia-related symptoms in patients with
permanent atrial fibrillation. Whereas diltiazem
and verapamil reduced arrhythmia-related
symptoms, no effect was observed with the
beta-blockers. The results demonstrated that
diltiazem 360 mg/day was the most effective
treatment for reducing heart rate. [16].
However, other authors have found that
360 mg/day of diltiazem was associated with
side effects in 75% of the patients with chronic
atrial fibrillation [17], suggesting 240 mg/day
diltiazem combined with digoxin as an effective
and safe regimen for the treatment of atrial
fibrillation. This discrepancy could be due to
the low number of patients included in both
studies. Additionally, a number of studies have
proposed the use of an intravenous bolus
followed by a continuous infusion of diltiazem
to control the ventricular response during atrial
fibrillation [6, 18].
Catheter ablation is the first choice of
treatment for supraventricular tachycardia
when episodes occur frequently and affect
patient’s quality of life [18]. However,
long-term preventive pharmacotherapy is an
alternative approach for some patients. In this
regard, some authors have proposed diltiazem
as a potential agent for supraventricular
tachycardia prophylaxis, after analyzing the
effect of diltiazem 270 mg every 8 h in 36
patients. The results showed that oral
diltiazem prevented induction and sustenance
of paroxysmal supraventricular tachycardia in
most of the patients [19]. In another study, the
efficacy and safety of flecaine and the
combination of diltiazem and propranolol,
were evaluated in the management of
supraventricular tachycardia [20]. The data
demonstrated that both treatments were
successful in 80% of patients, as all the
arrhythmic episodes were interrupted
out-of-hospital within 2 h. The authors
concluded that this therapeutic strategy
minimizes emergency assistance during
tachycardia recurrences.
A retrospective study evaluated 77 patients
with supraventricular tachycardia treated with
oral adenosine or intravenous diltiazem in the
emergency department [21]. The results
demonstrated that 71.9% of the patients
returned to normal sinus rhythm after the
higher dose of adenosine, whereas the
percentage of patients increased to 95% after
diltiazem (0.25 mg/kg). Therefore, diltiazem
may be a first-choice treatment in patients with
narrow-complex supraventricular tachycardia.
EXPERT RECOMMENDATIONS
According to the 2013 European guidelines for
the management of arterial hypertension [22],
the primary goal of treatment in these patients
is to achieve maximum reduction in the
long-term total risk of cardiovascular diseases.
The choice of a specific drug or combination
among the major antihypertensive drug classes
should take into account the patient’s previous
history and the presence of other disorders or
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conditions. Thus, the existence of angina
pectoris, hypertension, and supraventricular
tachycardia would favor the use of diltiazem
versus other agents.
In consonance with a number of studies that
have analyzed the effect of diltiazem in specific
cardiovascular diseases, and based on their own
clinical practice, the authors outline some
recommendations regarding the dosing of
diltiazem in the clinical practice.
For the treatment of high blood pressure, the
experts recommend that diltiazem dosage
should be at least 120 mg every 12 h, with 240
and 300 mg/day being the two most prescribed
antihypertensive doses (66.6% and 83.3% of the
experts, respectively). This recommendation is
based on the studies showing a larger effect of
these particular doses on the treatment of
hypertension; nevertheless, lower doses
(60–90 mg every 8 or 12 h) are indicated at
initiation of treatment or in patients with mild
blood pressure elevation, as well as in patients
with lower heart rates where the bradycardic
effect of diltiazemmay limit its beneficial action
in reducing blood pressure.
Additionally, a number of studies have
confirmed diltiazem effectiveness in reducing the
frequency of angina episodes and increasing
exercise tolerance; however, non-dihydropyridine
CBBs should not be used when there is a high risk
for heart failure due to reduced left ventricular
function. For the treatment of angina pectoris,
83.3%of the experts consider 120mg every 12 h as
the most common dose of diltiazem that achieves
efficacy in patients with angina, followed by a dose
of 300mg/day (50% of the experts) and
240mg/day (33% of the experts). The conclusion
is based on personal experience and clinical trial
results that have showed a better efficacy of those
doses in controlling chest pain. As previously
stated, the 60- or 90-mg doses administered every
8 or 12 h could also be useful for some patients,
particularly in patients with lower heart rate or
blood pressure, since both conditions restrict
diltiazem titration to higher doses.
In the treatment of atrial arrhythmias,
diltiazem is considered an effective rate-control
drug. The authors’ recommendation for patients
with atrial fibrillation or supraventricular
tachycardia is 120 mg every 12 h (66.6% of the
experts) as the proper dose for reducing the
heart rate. However, in older patients and in
those with mild arrhythmias, lower doses of
diltiazem (60 or 90 mg every 8 or 12 h) could be
useful. In the treatment of atrial fibrillation, the
dose may be increased to achieve the target
heart rate, usually between 60 and100 bpm,
taking into account the drug’s effect on blood
pressure, which can limit dose titration. To
prevent supraventricular tachycardia, the dose
should be between 90 and 120 mg every 12 h,
depending on the patient’s clinical response and
blood pressure.
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